(Q50506530)

14 March 2018

title

Phase I/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in Japan. (English)

1 reference

14 March 2018

main subject

myelodysplastic syndrome

1 reference

6

1 reference

14 March 2018

Kazuma Ohyashiki

9

object named as

Kazuma Ohyashiki

1 reference

14 March 2018

Yasuhiro Oki

1

1 reference

14 March 2018

Yutaka Kondo

2

1 reference

14 March 2018

Kazuhito Yamamoto

3

1 reference

14 March 2018

Michinori Ogura

4

1 reference

14 March 2018

Masanobu Kasai

5

1 reference

14 March 2018

Takashi Watanabe

7

1 reference

14 March 2018

Naokuni Uike

8

1 reference

14 March 2018

Shin-ichiro Okamoto

10

1 reference

14 March 2018

Kazunori Ohnishi

11

1 reference

14 March 2018

Akihiro Tomita

12

1 reference

14 March 2018

Yasushi Miyazaki

13

1 reference

14 March 2018

Kaoru Tohyama

14

1 reference

14 March 2018

Harumi Y Mukai

15

1 reference

14 March 2018

Tomomitsu Hotta

16

1 reference

14 March 2018

Masao Tomonaga

17

1 reference

14 March 2018

publication date

14 September 2012

1 reference

14 March 2018

published in

Cancer Science

1 reference

14 March 2018

volume

103

1 reference

14 March 2018

issue

10

1 reference

14 March 2018

page(s)

1839-1847

1 reference

14 March 2018

DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes

cites work

1 reference

12 December 2020

A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome

1 reference

12 December 2020

Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes

1 reference

12 December 2020

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

1 reference

12 December 2020

Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites

1 reference

12 December 2020

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

1 reference

12 December 2020

Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation fo

1 reference

12 December 2020

Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial

1 reference

12 December 2020

Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

1 reference

12 December 2020

International scoring system for evaluating prognosis in myelodysplastic syndromes

1 reference

12 December 2020

Report of an international working group to standardize response criteria for myelodysplastic syndromes.

1 reference

12 December 2020

Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas

1 reference

12 December 2020

A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements

1 reference

12 December 2020

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

1 reference

12 December 2020

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

12 December 2020

Worms gang up on bacteria

1 reference

12 December 2020

High-throughput methylation profiling by MCA coupled to CpG island microarray

1 reference

12 December 2020

Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

1 reference

12 December 2020

Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management

1 reference

12 December 2020

Genome architecture marked by retrotransposons modulates predisposition to DNA methylation in cancer

1 reference

12 December 2020

Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes.

1 reference

12 December 2020

Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines

1 reference

12 December 2020

Low-dose decitabine and high-risk MDS

1 reference

12 December 2020

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

12 December 2020

The fundamental role of epigenetic events in cancer

1 reference

12 December 2020

10.1111/J.1349-7006.2012.02386.X

Identifiers

DOI

1 reference

14 March 2018

release_g47ys7energ53h6ov2j2gfdwl4

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/g47ys7energ53h6ov2j2gfdwl4

24 November 2022

mapped directly with Wikidata item

1 reference

14 March 2018